Sanofi (SNY) Total Liabilities (2009 - 2026)
Sanofi's (SNY) quarterly Total Liabilities came in at $69.2 billion in Q2 2026, up 11.72% year-over-year from $61.9 billion in Q2 2025, and up 394.98% quarter-over-quarter from $14.0 billion in Q4 2025.
Analysis
Sanofi (SNY) Total Liabilities (2009 - 2026) Analysis & Trends
Sanofi has disclosed Total Liabilities across 18 years of filings, most recently posting $69.2 billion for Q2 2026.
- In Q2 2026, Total Liabilities rose 11.72% year-over-year to $69.2 billion; the TTM figure through Jun 2026 stood at $69.2 billion (up 11.72% YoY), while the FY2025 annual figure was $14.0 billion, down 76.51% from the prior year.
- Total Liabilities came in at $69.2 billion for Q2 2026 at Sanofi, up from $14.0 billion in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $69.2 billion in Q2 2026 to a low of $14.0 billion in Q4 2025.
- Average Total Liabilities over 5 years is $53.8 billion, with a median of $57.1 billion recorded in 2023.
- Year-over-year, Total Liabilities plunged 76.2% in 2025 and rose 11.72% in 2026.
- Over 5 years, Total Liabilities stood at $52.6 billion in 2022, then gained by 6.57% to $56.1 billion in 2023, then grew by 4.71% to $58.7 billion in 2024, then sank by 76.2% to $14.0 billion in 2025, then jumped by 394.98% to $69.2 billion in 2026.
- Per Business Quant data, the three most recent Total Liabilities figures were $69.2 billion in Q2 2026, $14.0 billion in Q4 2025, and $61.9 billion in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.14 Bn | 620.38 Bn | 17.26 Bn | 116.09 Bn |
| 2 | AbbVie | 451.04 Bn | 444.47 Bn | 12.70 Bn | 141.05 Bn |
| 3 | Merck | 357.43 Bn | 350.29 Bn | 12.21 Bn | 23.74 Bn |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn | 80.09 Bn |
| 5 | Pfizer | 157.52 Bn | 145.82 Bn | 10.94 Bn | 115.64 Bn |
| 6 | Sanofi | 52.14 Bn | 44.76 Bn | 10.79 Bn | 69.15 Bn |
| 7 | Revolution Medicines | 42.88 Bn | 42.88 Bn | - | 1.72 Bn |
| 8 | Incyte | 24.70 Bn | 20.16 Bn | 1.57 Bn | 1.53 Bn |
| 9 | United Therapeutics | 21.47 Bn | 18.80 Bn | 683.80 Mn | 819.80 Mn |
| 10 | Neurocrine Biosciences | 15.82 Bn | 15.43 Bn | 935.80 Mn | 1.67 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 69.15 Bn |
| Dec 31, 2025 | 13.97 Bn |
| Jun 30, 2025 | 61.90 Bn |
| Dec 31, 2024 | 58.71 Bn |
| Jun 30, 2024 | 61.12 Bn |
| Dec 31, 2023 | 56.07 Bn |
| Jun 30, 2023 | 57.07 Bn |
| Dec 31, 2022 | 52.61 Bn |
| Jun 30, 2022 | 53.91 Bn |
| Dec 31, 2021 | 58.58 Bn |
| Jun 30, 2021 | 59.11 Bn |
| Dec 31, 2020 | 61.00 Bn |
| Jun 30, 2020 | 57.64 Bn |
| Dec 31, 2019 | 3.09 Bn |
| Jun 30, 2019 | 60.71 Bn |
| Dec 31, 2018 | 2.32 Bn |
| Sep 30, 2018 | 458.27 Mn |
| Mar 31, 2018 | 65.62 Bn |
| Dec 31, 2017 | 2.74 Bn |
| Jun 30, 2017 | 48.47 Bn |